Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 15.30 Delayed Data As of Aug 18 |  -0.15 / -0.97%Today’s Change | 10.66 Today|||52-Week Range 19.90 | +1.66% Year-to-Date |
| Teva Must Clear Three Big Hurdles to Reclaim Its Perch Aug 15 / TheStreet.com - Paid Partner Content |
| Previous close | 15.45 |
| Today’s open | 15.30 |
| Day’s range | 15.16 - 15.55 |
| Volume | 337,723 |
| Average volume (3 months) | 734,507 |
| Market cap | $1.2B |
| Dividend yield | -- |
| Earnings growth (last year) | +76.52% |
| Earnings growth (this year) | -250.68% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +22.27% |
| P/E ratio | NM |
| Price/Sales | 9.43 |
| Price/Book | 2.92 |
| Today’s change | Today’s % change | |
|---|---|---|
| XLRNAcceleron Pharma Inc | -1.31 | -3.80% |
| NDRMNeuroderm Ltd | 0.00 | 0.00% |
| RTRXRetrophin Inc | +0.22 | +0.93% |
| SGMOSangamo Therapeutics... | -0.35 | -3.41% |
| Next reporting date | November 8, 2017 |
| EPS forecast (this quarter) | -$0.35 |
| Annual revenue (last year) | $109.6M |
| Annual profit (last year) | -$21.0M |
| Net profit margin | -19.16% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Craig A. Wheeler |
Chief Financial Officer, Treasurer & Senior VP Scott M. Storer |
Corporate headquarters Cambridge, Massachusetts |
